Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel Passeri Insider Profile
11 Followers
Daniel Passeri, Director at Curis, holds 164.58K shares in Cue Biopharma (Ticker: CUE), holds 211.80K shares in Curis (Ticker: CRIS). Most recently, Daniel Passeri Bought ― shares of Cue Biopharma on Dec 18, 2024 for an estimated value of 30.90K.
Profitable Transactions
2 out of 7 Profitable Transactions
Average Return
+34.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Daniel Passeri
Daniel Passeri's Trading History
Curis
Jan 07, 2016
Director
Uninformative Buy
20.25K
$652.34K
Cue Biopharma
Dec 18, 2024
CEO, Director
Informative Buy
30.90K
$166.22K
List of latest transactions for each holding click on a transaction to see Daniel Passeri's performance on stock
You May Also Like
Daniel Passeri insider profile FAQ
What is the percentage of profitable transactions made by Daniel Passeri?
The percentage of profitable transactions made by Daniel Passeri is 29%.
What is the average return per transaction made by Daniel Passeri?
The average return per transaction made by Daniel Passeri is 34.50%.
What stocks does Daniel Passeri hold?
Daniel Passeri holds: CRIS, CUE stocks.
What was Daniel Passeri’s latest transaction?
Daniel Passeri latest transaction was an Informative Buy of $30.90K.
What was Daniel Passeri's most profitable transaction?
Daniel Passeri’s most profitable transaction was an Informative Buy of CUE stock on June 7, 2019. The return on the trade was 227.10%.
What is Daniel Passeri's role in Curis?
Daniel Passeri's role in Curis is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.